Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF

Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography, and Histopathology

(2014) Junjie Li et al.   Translational Oncology

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Contrasting effects of sunitinib within in vivo models of metastasis

(2012) Jonathan C. Welti et al.   ANGIOGENESIS

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

(2012) P. Nathan et al.   CLINICAL CANCER RESEARCH

Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594

(2012) Caroline J. Breitbach et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody

(2012) Sandeep S. Patil et al.   PLoS One

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

(2011) Jeong Heo et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Amgen spikes interest in live virus vaccines for hard-to-treat cancers

(2011) Charlie Schmidt   NATURE BIOTECHNOLOGY

Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models

(2009) K. Guse et al.   JOURNAL OF VIROLOGY

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy

(2009) A. Frentzen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma

(2008) Ta-Chiang Liu et al.   MOLECULAR THERAPY